Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Michael Young who wrote (3955)	6/5/2001 8:11:06 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 52153

Cramer potato (MY) is going to screw-up another company (DCGN), after leaving GZTC. So, how many millions did you make for your customer, GZTC shareholders? Now, watch Cramer turn into genomic expert! When he first time mentioned genomic, it is time to bail out, and short selectively. For the record, Mike "ONLY" activity at GZTC for last 12 months (thinking only how to unload). He never owned single share! YOUNG MICHAEL VP 7/24/2000 Sell 6,600 $34.190 0 YOUNG MICHAEL VP 5/30/2000 Sell 63,720 $18.250 0 YOUNG MICHAEL VP 5/18/2000 Sell 48,920 $20.530 0 Miljenko Tuesday June 5, 8:00 am Eastern Time Press Release SOURCE: deCODE genetics deCODE Names Michael Young Vice President of Business Development REYKJAVIK, Iceland, June 5 /PRNewswire/ -- deCODE genetics (Nasdaq: DCGN; Nasdaq Europe) has appointed Michael Young to the new position of Vice President of Business Development, effective immediately. Mr. Young will spearhead the company's strategy of aggressively expanding corporate and commercial alliances across the range of its research and product development programs. Mr. Young, 49, brings to deCODE 20 years of top-level business development experience in the global biopharmaceutical industry. He joins deCODE from Genzyme Transgenics, where for the past six years he served as Vice President of Commercial Development and was instrumental in converting the company into a world leader in the development of transgenic therapeutics. Previously, Mr. Young was the head of business development at PerSeptive BioSystems, and has also worked at Millipore Corporation, Verax Corporation and Ventrex Laboratories. Mr. Young will oversee the development of new partnerships for deCODE's rapidly expanding research programs and product offerings in gene discovery, pharmacogenomics, drug and diagnostic development, as well as database and bioinformatics products and services. ``We are very pleased to welcome Mike on board at deCODE,'' said Kari Stefansson, CEO. ``His experience, track record, and detailed knowledge of the industry in the US, Europe and Asia offer ideal leadership for our expanding business development efforts. I believe he will play a key role in maximizing the worldwide opportunities for deCODE's business as we continue to turn our research into products on the market.'' ``deCODE is a world leader in genomics research and I am very excited by the opportunity to leverage that leadership in the formation of new business partnerships,'' commented Mike Young, Vice President of Business Development at deCODE genetics. ``The industry is focusing ever more downstream towards the development and marketing of new products and I look forward to turning deCODE's unique scientific resources and achievements into value in the global pharmaceutical and healthcare marketplace.'' deCODE genetics (http://www.decode.com), based in Reykjavik, Iceland, is conducting research into the inherited causes of common diseases. The company has three main business units: discovery services -- including disease-gene research, drug target identification and pharmacogenomic services; database services; and bioinformatics tools and services. deCODE is using its population approach to turn raw genomics data into products and services for the global healthcare industry. Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on strategic partners, ability to obtain financing, competitive products and other risks identified in deCODE's filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. deCODE undertakes no obligation to publicly release any revisions to these forward-looking statements resulting from events or circumstances after the date hereof.